SA
DXCM icon

Strategic Advocates’s DexCom DXCM Stock Holding History

Strategic Advocates’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5
Closed -$335 – 357
2025
Q4 		$335 Hold
5
– – ﹤0.01% 567
2025
Q3 		$336 Buy
+5
New +$396 ﹤0.01% 543
2024
Q4 		– Sell
-4,472
Closed -$300K – 115
2024
Q3 		$300K Sell
4,472
-1,807
-29% -$148K 0.11% 95
2024
Q2 		$712K Buy
+6,279
New +$794K 0.28% 51

Other funds holding DXCM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Strategic Advocates's DXCM Position: Q1 2026 in Review

Strategic Advocates sold out of DexCom (DXCM) in Q1 2026, closing a stake of 5 shares — an estimated $335 sold.

Strategic Advocates first reported a position in DXCM in Q2 2024 and held it in 4 quarters. The position peaked at $712K in Q2 2024. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Strategic Advocates reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
  • Strategic Advocates sold 5 DexCom shares in Q1 2026, an estimated $335.
  • Strategic Advocates first reported a position in DexCom in Q2 2024 and held it in 4 quarters.
  • Strategic Advocates's DexCom position peaked at $712K in Q2 2024.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.